US Pharma MarketingBristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed
Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be worth up to $15.2 billion.
Source: FierceBiotech